Development and internal validation of a modified Caprini score for postoperative venous thromboembolism in gastrointestinal adenocarcinoma: a retrospective cohort study
This retrospective cohort study developed and internally validated a modified Caprini score incorporating tumor stage, operative time, blood transfusion, and postoperative D-dimer levels, which demonstrated significantly improved discrimination for predicting venous thromboembolism in gastrointestinal adenocarcinoma patients compared to the conventional score, though its clinical utility requires further external validation.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Every year, millions of people undergo surgery to remove cancer from their stomach or intestines. While the operation itself is a critical step toward healing, the recovery period carries a hidden danger: blood clots. When the body is under the stress of a major operation and the presence of cancer, the blood can become too thick and prone to clotting. These clots, known medically as venous thromboembolism, can form in the legs and travel to the lungs, causing a potentially fatal blockage. To prevent this, doctors rely on a standard checklist called the Caprini score. This tool assigns points for various risk factors, such as a patient's age, the type of surgery, and their medical history, to estimate how likely they are to develop a clot. However, for patients with gastrointestinal cancer, this checklist often hits a wall. Because almost every patient with this type of cancer already has a high score due to the disease and the surgery itself, the tool struggles to tell the difference between someone who is merely at risk and someone who is in immediate, critical danger. It is like having a thermometer that reads "hot" for everyone in a fever ward, making it impossible to identify who needs the most urgent cooling.
Researchers at Huzhou Central Hospital in China set out to fix this blind spot. They looked back at the records of 220 patients who had undergone surgery for gastrointestinal adenocarcinoma between June 2023 and December 2024. Their goal was to see if they could find specific details that the standard checklist missed, details that could help separate the patients who would develop clots from those who would not. The team examined a wide range of data, including how long the surgery lasted, whether the patient needed a blood transfusion during the procedure, the stage of the cancer, and a specific blood test taken the day after surgery. They focused on a marker called D-dimer, a substance that rises when the body is trying to break down a clot. By analyzing these factors alongside the standard score, they hoped to build a more precise tool.
The study found that the standard checklist was indeed too blunt for this specific group of patients. In the group of 220 people, 49 developed blood clots after their surgery. When the researchers applied the traditional scoring method, it failed to distinguish well between those who got clots and those who did not. To improve this, the team created a modified version of the score. They kept the original points but added four new factors that provided fresh information: if the cancer had spread to nearby lymph nodes or other organs, if the surgery lasted longer than 240 minutes, if the patient received a blood transfusion, and if the D-dimer level on the first day after surgery was higher than 5.0 mg/L. Each of these four factors added one extra point to the patient's total score.
The results showed that this new, modified score was significantly better at predicting who would develop a clot. While the old score had an AUC of 0.57, the new score improved that to roughly 0.73. This means the new tool could more reliably identify the patients who were truly at high risk. The researchers also checked how well the score worked across different groups of patients and found that it remained stable, though they noted that the very highest-risk group was small, making those specific numbers less certain. They observed that patients with advanced cancer stages, longer surgeries, blood transfusions, or high D-dimer levels were indeed much more likely to develop clots.
Despite the improvement, the authors were careful not to declare the problem solved. They emphasized that their work was a single study at one hospital, and the new score needs to be tested on a much larger and more diverse group of people before it can be used as a standard rule in hospitals. The timing of the blood test was also a factor; because the test was done the day after surgery, it is possible that for some patients, the clot had already formed before the blood was drawn, meaning the test was detecting an existing problem rather than predicting a future one. The researchers concluded that while their modified score offers a clearer view of the risks for these specific patients, it remains a work in progress. It is a promising step toward a more personalized approach to safety, but it requires further validation to ensure it can be trusted to guide life-saving decisions in operating rooms around the world.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.